A detailed history of Swiss National Bank transactions in Biogen Inc. stock. As of the latest transaction made, Swiss National Bank holds 432,100 shares of BIIB stock, worth $64.4 Million. This represents 0.06% of its overall portfolio holdings.

Number of Shares
432,100
Previous 430,400 0.39%
Holding current value
$64.4 Million
Previous $99.8 Million 16.05%
% of portfolio
0.06%
Previous 0.07%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 07, 2024

BUY
$189.07 - $236.8 $321,419 - $402,560
1,700 Added 0.39%
432,100 $83.8 Million
Q2 2024

Aug 08, 2024

SELL
$190.52 - $236.72 $666,820 - $828,520
-3,500 Reduced 0.81%
430,400 $99.8 Million
Q1 2024

May 07, 2024

SELL
$212.02 - $267.71 $4.03 Million - $5.09 Million
-19,000 Reduced 4.2%
433,900 $93.6 Million
Q4 2023

Feb 06, 2024

SELL
$222.59 - $267.94 $2.83 Million - $3.4 Million
-12,700 Reduced 2.73%
452,900 $117 Million
Q3 2023

Nov 08, 2023

SELL
$253.3 - $285.89 $14.3 Million - $16.1 Million
-56,300 Reduced 10.79%
465,600 $120 Million
Q2 2023

Aug 09, 2023

SELL
$275.25 - $318.06 $13.7 Million - $15.8 Million
-49,600 Reduced 8.68%
521,900 $149 Million
Q1 2023

May 10, 2023

SELL
$256.56 - $292.34 $4.7 Million - $5.35 Million
-18,300 Reduced 3.1%
571,500 $159 Million
Q4 2022

Feb 08, 2023

SELL
$252.44 - $306.72 $11.4 Million - $13.8 Million
-44,972 Reduced 7.08%
589,800 $163 Million
Q3 2022

Nov 09, 2022

SELL
$194.69 - $268.46 $506,194 - $697,996
-2,600 Reduced 0.41%
634,772 $169 Million
Q2 2022

Aug 09, 2022

BUY
$187.54 - $223.02 $206,294 - $245,322
1,100 Added 0.17%
637,372 $130 Million
Q1 2022

May 09, 2022

BUY
$193.77 - $244.14 $13.5 Million - $17 Million
69,700 Added 12.3%
636,272 $134 Million
Q4 2021

Feb 08, 2022

SELL
$223.92 - $287.77 $6.43 Million - $8.26 Million
-28,700 Reduced 4.82%
566,572 $136 Million
Q3 2021

Nov 08, 2021

SELL
$282.99 - $369.05 $7.3 Million - $9.52 Million
-25,800 Reduced 4.15%
595,272 $168 Million
Q2 2021

Aug 06, 2021

BUY
$259.0 - $414.71 $7.59 Million - $12.2 Million
29,314 Added 4.95%
621,072 $215 Million
Q1 2021

May 07, 2021

SELL
$242.95 - $284.63 $1.51 Million - $1.76 Million
-6,200 Reduced 1.04%
591,758 $166 Million
Q4 2020

Feb 05, 2021

SELL
$236.26 - $355.63 $8.81 Million - $13.3 Million
-37,300 Reduced 5.87%
597,958 $146 Million
Q3 2020

Nov 09, 2020

SELL
$264.77 - $305.71 $14.1 Million - $16.3 Million
-53,200 Reduced 7.73%
635,258 $180 Million
Q2 2020

Aug 05, 2020

SELL
$258.66 - $342.55 $3.08 Million - $4.08 Million
-11,900 Reduced 1.7%
688,458 $184 Million
Q1 2020

May 08, 2020

BUY
$268.85 - $341.04 $31.9 Million - $40.5 Million
118,800 Added 20.43%
700,358 $222 Million
Q4 2019

Feb 06, 2020

SELL
$220.06 - $304.07 $12.9 Million - $17.9 Million
-58,800 Reduced 9.18%
581,558 $173 Million
Q3 2019

Nov 12, 2019

SELL
$217.44 - $243.88 $182,867 - $205,103
-841 Reduced 0.13%
640,358 $149 Million
Q2 2019

Aug 02, 2019

SELL
$219.29 - $241.72 $6.89 Million - $7.59 Million
-31,400 Reduced 4.67%
641,199 $150 Million
Q1 2019

May 10, 2019

BUY
$216.71 - $338.96 $3.86 Million - $6.03 Million
17,800 Added 2.72%
672,599 $159 Million
Q4 2018

Feb 13, 2019

SELL
$278.5 - $352.75 $5.26 Million - $6.67 Million
-18,900 Reduced 2.81%
654,799 $197 Million
Q3 2018

Nov 08, 2018

SELL
$293.51 - $383.83 $7.63 Million - $9.98 Million
-26,000 Reduced 3.72%
673,699 $238 Million
Q2 2018

Aug 09, 2018

BUY
$257.52 - $306.91 $5.46 Million - $6.51 Million
21,200 Added 3.12%
699,699 $203 Million
Q1 2018

May 04, 2018

SELL
$260.13 - $367.91 $26.6 Million - $37.7 Million
-102,400 Reduced 13.11%
678,499 $186 Million
Q4 2017

Feb 07, 2018

SELL
$307.64 - $344.58 $2.43 Million - $2.72 Million
-7,900 Reduced 1.0%
780,899 $249 Million
Q3 2017

Nov 03, 2017

BUY
$281.15 - $329.69 $222 Million - $260 Million
788,799
788,799 $247 Million

Others Institutions Holding BIIB

About BIOGEN INC.


  • Ticker BIIB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 144,000,992
  • Market Cap $21.5B
  • Description
  • Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...
More about BIIB
Track This Portfolio

Track Swiss National Bank Portfolio

Follow Swiss National Bank and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Swiss National Bank, based on Form 13F filings with the SEC.

News

Stay updated on Swiss National Bank with notifications on news.